Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JOSE E GAMEZ

Allopathic & Osteopathic Physicians Psychiatry & Neurology Psychiatry

NPI
1134210271
CMS profile
96150
Location
HIALEAH, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$162,794.17

275 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

By paying entity

PY2023 · entire year · sorted by reported total

Page 4 of 6; records 151–200 of 275 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JOSE E GAMEZ

NPI 1134210271 · CMS profile ID 96150

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Psychiatry

HIALEAH, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 4 of 6; records 151–200 of 275 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1134210271?year=2023&recipient=provider&page=4#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JOSE E GAMEZ, NPI 1134210271, CMS profile ID 96150. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 6; records 151–200 of 275 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1134210271?year=2023&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). JOSE E GAMEZ, NPI 1134210271, CMS profile ID 96150. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 6; records 151–200 of 275 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1134210271?year=2023&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
JOSE E GAMEZ, NPI 1134210271, CMS profile ID 96150, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 6; records 151–200 of 275 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1134210271?year=2023&recipient=provider&page=4#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

275 matching records · $162,794.17 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 275 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 151–200 of 275.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Teva Pharmaceuticals USA, Inc. $2,600.0006/22/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056649689 CMS
Corium, LLC $6.1306/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 978436973 CMS
ACADIA Pharmaceuticals Inc $214.0806/08/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053131883 CMS
ACADIA Pharmaceuticals Inc $24.3006/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053131887 CMS
Janssen Pharmaceuticals, Inc $80.0006/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 987767917 CMS
Otsuka America Pharmaceutical, Inc. $26.0806/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014350189 CMS
Otsuka America Pharmaceutical, Inc. $25.2605/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014350181 CMS
Neurocrine Biosciences, Inc. $2,975.0005/23/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1052024513 CMS
Bausch Health US, LLC $22.4005/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1046945035 CMS
ACADIA Pharmaceuticals Inc $1,250.0005/16/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053131879 CMS
Otsuka America Pharmaceutical, Inc. $125.0005/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014350173 CMS
Teva Pharmaceuticals USA, Inc. $41.5405/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056649751 CMS
Teva Pharmaceuticals USA, Inc. $59.9905/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056649753 CMS
Teva Pharmaceuticals USA, Inc. $44.7105/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056649755 CMS
Teva Pharmaceuticals USA, Inc. $35.0005/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056649761 CMS
Teva Pharmaceuticals USA, Inc. $38.5205/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056649765 CMS
Teva Pharmaceuticals USA, Inc. $54.8005/13/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056649979 CMS
Teva Pharmaceuticals USA, Inc. $67.1605/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056649759 CMS
Teva Pharmaceuticals USA, Inc. $120.0005/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056649767 CMS
Teva Pharmaceuticals USA, Inc. $3,270.0005/12/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056649977 CMS
Teva Pharmaceuticals USA, Inc. $185.0005/12/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056649981 CMS
Teva Pharmaceuticals USA, Inc. $249.0005/12/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056649983 CMS
Teva Pharmaceuticals USA, Inc. $575.1005/12/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056649985 CMS
Corium, LLC $12.4505/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 978436965 CMS
ABBVIE INC. $14.9005/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997311039 CMS
ACADIA Pharmaceuticals Inc $24.0104/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053131875 CMS
Bausch Health US, LLC $24.9304/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1046945015 CMS
Teva Pharmaceuticals USA, Inc. $43.2704/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056649649 CMS
Neurocrine Biosciences, Inc. $20.4704/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1052023921 CMS
Neurocrine Biosciences, Inc. $2,975.0004/19/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1052024509 CMS
ACADIA Pharmaceuticals Inc $1,050.0004/18/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053131863 CMS
ACADIA Pharmaceuticals Inc $13.5104/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053131867 CMS
ACADIA Pharmaceuticals Inc $1.8604/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053131871 CMS
ACADIA Pharmaceuticals Inc $143.0904/14/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053131855 CMS
ACADIA Pharmaceuticals Inc $42.8804/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053131859 CMS
Otsuka America Pharmaceutical, Inc. $26.3704/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014350165 CMS
ABBVIE INC. $22.7104/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997311037 CMS
Neurocrine Biosciences, Inc. $33.7804/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1052023815 CMS
ACADIA Pharmaceuticals Inc $42.1003/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053131815 CMS
ACADIA Pharmaceuticals Inc $18.0403/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053131819 CMS
ACADIA Pharmaceuticals Inc $45.7103/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053131823 CMS
ACADIA Pharmaceuticals Inc $51.6903/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053131827 CMS
ACADIA Pharmaceuticals Inc $21.5103/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053131831 CMS
ACADIA Pharmaceuticals Inc $315.2703/31/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053131835 CMS
ACADIA Pharmaceuticals Inc $6.0303/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053131839 CMS
ACADIA Pharmaceuticals Inc $67.8403/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053131843 CMS
ACADIA Pharmaceuticals Inc $6,500.0003/31/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053131847 CMS
ACADIA Pharmaceuticals Inc $118.2103/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053131851 CMS
IDORSIA PHARMACEUTICALS US INC $86.3503/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1034255457 CMS
Neurocrine Biosciences, Inc. $117.4303/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1052023823 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $46,961.69 105
PY2020 $26,688.80 75
PY2021 $31,225.07 86
PY2022 $96,287.86 149
PY2023 $162,794.17 275
PY2024 $117,252.32 200
PY2025 $75,934.56 146

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $2,200,446.48 507
PY2024 Principal investigator $3,604,045.79 221
PY2023 Principal investigator $2,030,827.58 147
PY2022 Recipient $83.96 2
PY2022 Principal investigator $732,459.25 65
PY2021 Principal investigator $1,515,129.73 87
PY2020 Recipient $774.86 5
PY2020 Principal investigator $1,694,395.89 146
PY2019 Recipient $4,632.29 21
PY2019 Principal investigator $2,435,859.61 244

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

507 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Novo Nordisk AS $1,441.80 12/22/2025 Non-covered Recipient Entity
GALIZ RESEARCH, LLC
NN6535-4725 No dispute reported 06/30/2026 1213745186
Principal investigator 1 Novo Nordisk AS $3,000.00 12/22/2025 Non-covered Recipient Entity
GALIZ RESEARCH, LLC
NN6535-4725 No dispute reported 06/30/2026 1213765734
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,360.00 12/05/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242368767
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,360.00 12/05/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242368769
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,430.00 12/05/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242368771
Principal investigator 1 ABBVIE INC. $7,196.60 12/01/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
A 52-week, Phase 2, Open-label Trial to Evaluate the Long-term Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia No dispute reported 06/30/2026 1202526230
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $1,800.00 12/01/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242367869
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $750.00 12/01/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242367871
Principal investigator 1 Janssen Research & Development, LLC $2,781.00 12/01/2025 Non-covered Recipient Entity
Galiz Research, Llc
A Study of Aticaprant in Adult and Elderly Participants With Major Depressive Disorder (MDD) (VENTURA-LT) No dispute reported 06/30/2026 1175191137
Principal investigator 1 Boehringer Ingelheim International GmbH $1,284.00 11/25/2025 Non-covered Recipient Entity
Galiz Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220685267
Principal investigator 1 Boehringer Ingelheim International GmbH $1,284.00 11/25/2025 Non-covered Recipient Entity
Galiz Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220685269
Principal investigator 1 Boehringer Ingelheim International GmbH $1,284.00 11/25/2025 Non-covered Recipient Entity
Galiz Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220685271
Principal investigator 1 Boehringer Ingelheim International GmbH $1,284.00 11/25/2025 Non-covered Recipient Entity
Galiz Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220685273
Principal investigator 1 Boehringer Ingelheim International GmbH $1,284.00 11/25/2025 Non-covered Recipient Entity
Galiz Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220685275
Principal investigator 1 Boehringer Ingelheim International GmbH $1,284.00 11/25/2025 Non-covered Recipient Entity
Galiz Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220685277
Principal investigator 1 Boehringer Ingelheim International GmbH $1,284.00 11/25/2025 Non-covered Recipient Entity
Galiz Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220685279
Principal investigator 1 Boehringer Ingelheim International GmbH $1,284.00 11/25/2025 Non-covered Recipient Entity
Galiz Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220685281
Principal investigator 1 Boehringer Ingelheim International GmbH $1,284.00 11/25/2025 Non-covered Recipient Entity
Galiz Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220685283
Principal investigator 1 Boehringer Ingelheim International GmbH $1,284.00 11/25/2025 Non-covered Recipient Entity
Galiz Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220685285
Principal investigator 1 Boehringer Ingelheim International GmbH $1,284.00 11/25/2025 Non-covered Recipient Entity
Galiz Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220685287
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 11/25/2025 Non-covered Recipient Entity
Galiz Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220685289
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 11/25/2025 Non-covered Recipient Entity
Galiz Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220685291
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 11/25/2025 Non-covered Recipient Entity
Galiz Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220685293
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 11/25/2025 Non-covered Recipient Entity
Galiz Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220685295
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 11/25/2025 Non-covered Recipient Entity
Galiz Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220685297
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 11/25/2025 Non-covered Recipient Entity
Galiz Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220685299
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 11/25/2025 Non-covered Recipient Entity
Galiz Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220685301
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 11/25/2025 Non-covered Recipient Entity
Galiz Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220685303
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 11/25/2025 Non-covered Recipient Entity
Galiz Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220685305
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 11/25/2025 Non-covered Recipient Entity
Galiz Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220685307
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 11/25/2025 Non-covered Recipient Entity
Galiz Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220685309
Principal investigator 1 Boehringer Ingelheim International GmbH $1,339.00 11/25/2025 Non-covered Recipient Entity
Galiz Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220685311
Principal investigator 1 Boehringer Ingelheim International GmbH $1,339.00 11/25/2025 Non-covered Recipient Entity
Galiz Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220685313
Principal investigator 1 Boehringer Ingelheim International GmbH $1,339.00 11/25/2025 Non-covered Recipient Entity
Galiz Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220685315
Principal investigator 1 Boehringer Ingelheim International GmbH $1,339.00 11/25/2025 Non-covered Recipient Entity
Galiz Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220685317
Principal investigator 1 Boehringer Ingelheim International GmbH $1,339.00 11/25/2025 Non-covered Recipient Entity
Galiz Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220685319
Principal investigator 1 Boehringer Ingelheim International GmbH $1,339.00 11/25/2025 Non-covered Recipient Entity
Galiz Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220685321
Principal investigator 1 Boehringer Ingelheim International GmbH $1,339.00 11/25/2025 Non-covered Recipient Entity
Galiz Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220685323
Principal investigator 1 Boehringer Ingelheim International GmbH $1,339.00 11/25/2025 Non-covered Recipient Entity
Galiz Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220685325
Principal investigator 1 Boehringer Ingelheim International GmbH $1,339.00 11/25/2025 Non-covered Recipient Entity
Galiz Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220685327
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 11/25/2025 Non-covered Recipient Entity
Galiz Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220685329
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 11/25/2025 Non-covered Recipient Entity
Galiz Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220685331
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 11/25/2025 Non-covered Recipient Entity
Galiz Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220685333
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 11/25/2025 Non-covered Recipient Entity
Galiz Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220685335
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 11/25/2025 Non-covered Recipient Entity
Galiz Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220685337
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 11/25/2025 Non-covered Recipient Entity
Galiz Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220685339
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 11/25/2025 Non-covered Recipient Entity
Galiz Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220685341
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 11/25/2025 Non-covered Recipient Entity
Galiz Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220685343
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 11/25/2025 Non-covered Recipient Entity
Galiz Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220685345
Principal investigator 1 UCB SA $8,968.00 11/14/2025 Non-covered Recipient Entity
SC3 RESEARCH GROUP INC
A PATIENT- AND INVESTIGATOR-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF BEPRANEMAB (UCB0107) IN STUDY PARTICIPANTS WITH PRODROMAL TO MILD ALZHEIMERS DISEASE (AD), FOLLOWED BY AN OPEN-LABEL EXTENSION PERIOD No dispute reported 06/30/2026 1246658836
Principal investigator 1 LivaNova USA, Inc. $97.50 11/08/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
RECOVER No dispute reported 06/30/2026 1245543832
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,632.00 11/07/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242365869
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $720.00 11/07/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242365873
Principal investigator 1 Novo Nordisk AS $750.00 10/29/2025 Non-covered Recipient Entity
GALIZ RESEARCH, LLC
NN6535-4725 No dispute reported 06/30/2026 1213707013
Principal investigator 1 Novo Nordisk AS $750.00 10/29/2025 Non-covered Recipient Entity
GALIZ RESEARCH, LLC
NN6535-4725 No dispute reported 06/30/2026 1213711193
Principal investigator 1 Novo Nordisk AS $400.00 10/29/2025 Non-covered Recipient Entity
GALIZ RESEARCH, LLC
NN6535-4725 No dispute reported 06/30/2026 1213767446
Principal investigator 1 ABBVIE INC. $22,138.83 10/27/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
A 52-week, Phase 2, Open-label Trial to Evaluate the Long-term Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia No dispute reported 06/30/2026 1202518701
Principal investigator 1 Boehringer Ingelheim International GmbH $8,633.70 10/22/2025 Non-covered Recipient Entity
Galiz Research
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220685191
Principal investigator 1 Janssen Research & Development, LLC $10,556.00 10/17/2025 Non-covered Recipient Entity
Galiz Research, Llc
A Study of Aticaprant in Adult and Elderly Participants With Major Depressive Disorder (MDD) (VENTURA-LT) No dispute reported 06/30/2026 1175191152
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,360.00 10/10/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242363547
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,360.00 10/10/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242363549
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,360.00 10/10/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242363551
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,430.00 10/10/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242363553
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,430.00 10/10/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242363555
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,430.00 10/10/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242363557
Principal investigator 1 ABBVIE INC. $1,000.00 09/29/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
A 52-week, Phase 2, Open-label Trial to Evaluate the Long-term Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia No dispute reported 06/30/2026 1202512762
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,430.00 09/22/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242359124
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $45.00 09/22/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242359126
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,430.00 09/22/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242359128
Principal investigator 1 Novo Nordisk AS $747.90 09/19/2025 Non-covered Recipient Entity
GALIZ RESEARCH, LLC
NN6535-4725 No dispute reported 06/30/2026 1213771234
Principal investigator 1 ABBVIE INC. $880.73 09/17/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
A 52-week, Phase 2, Open-label Trial to Evaluate the Long-term Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia No dispute reported 06/30/2026 1202511270
Principal investigator 1 ABBVIE INC. $5,306.45 09/10/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
A 52-week, Phase 2, Open-label Trial to Evaluate the Long-term Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia No dispute reported 06/30/2026 1202510586
Principal investigator 1 Boehringer Ingelheim International GmbH $2,910.00 09/05/2025 Non-covered Recipient Entity
Galiz Research
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220685187
Principal investigator 1 Boehringer Ingelheim International GmbH $572.00 09/03/2025 Non-covered Recipient Entity
Galiz Research
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220685185
Principal investigator 1 Boehringer Ingelheim International GmbH $500.00 09/03/2025 Non-covered Recipient Entity
Galiz Research
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220685189
Principal investigator 1 Boehringer Ingelheim International GmbH $2,006.00 08/22/2025 Non-covered Recipient Entity
Galiz Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220685201
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 08/22/2025 Non-covered Recipient Entity
Galiz Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220685203
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 08/22/2025 Non-covered Recipient Entity
Galiz Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220685205
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 08/22/2025 Non-covered Recipient Entity
Galiz Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220685207
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 08/22/2025 Non-covered Recipient Entity
Galiz Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220685209
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 08/22/2025 Non-covered Recipient Entity
Galiz Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220685211
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 08/22/2025 Non-covered Recipient Entity
Galiz Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220685213
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 08/22/2025 Non-covered Recipient Entity
Galiz Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220685215
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 08/22/2025 Non-covered Recipient Entity
Galiz Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220685217
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 08/22/2025 Non-covered Recipient Entity
Galiz Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220685219
Principal investigator 1 Boehringer Ingelheim International GmbH $2,006.00 08/22/2025 Non-covered Recipient Entity
Galiz Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220685221
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 08/22/2025 Non-covered Recipient Entity
Galiz Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220685223
Principal investigator 1 Boehringer Ingelheim International GmbH $2,006.00 08/22/2025 Non-covered Recipient Entity
Galiz Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220685225
Principal investigator 1 Boehringer Ingelheim International GmbH $2,006.00 08/22/2025 Non-covered Recipient Entity
Galiz Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220685227
Principal investigator 1 Boehringer Ingelheim International GmbH $2,006.00 08/22/2025 Non-covered Recipient Entity
Galiz Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220685229
Principal investigator 1 Boehringer Ingelheim International GmbH $2,006.00 08/22/2025 Non-covered Recipient Entity
Galiz Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220685231
Principal investigator 1 Boehringer Ingelheim International GmbH $2,006.00 08/22/2025 Non-covered Recipient Entity
Galiz Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220685233
Principal investigator 1 Boehringer Ingelheim International GmbH $2,006.00 08/22/2025 Non-covered Recipient Entity
Galiz Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220685235
Principal investigator 1 Boehringer Ingelheim International GmbH $2,006.00 08/22/2025 Non-covered Recipient Entity
Galiz Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220685237
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 08/22/2025 Non-covered Recipient Entity
Galiz Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220685239
Principal investigator 1 Boehringer Ingelheim International GmbH $2,006.00 08/22/2025 Non-covered Recipient Entity
Galiz Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220685241
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 08/22/2025 Non-covered Recipient Entity
Galiz Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220685243
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 08/22/2025 Non-covered Recipient Entity
Galiz Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220685245
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 08/22/2025 Non-covered Recipient Entity
Galiz Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220685247
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 08/22/2025 Non-covered Recipient Entity
Galiz Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220685249
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 08/22/2025 Non-covered Recipient Entity
Galiz Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220685251
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 08/22/2025 Non-covered Recipient Entity
Galiz Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220685253
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 08/22/2025 Non-covered Recipient Entity
Galiz Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220685255
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 08/22/2025 Non-covered Recipient Entity
Galiz Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220685257
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 08/22/2025 Non-covered Recipient Entity
Galiz Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220685259
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 08/22/2025 Non-covered Recipient Entity
Galiz Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220685261
Principal investigator 1 Boehringer Ingelheim International GmbH $2,006.00 08/22/2025 Non-covered Recipient Entity
Galiz Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220685263
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 08/22/2025 Non-covered Recipient Entity
Galiz Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220685265
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $4,097.80 08/14/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1244047628
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $81.20 08/14/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1244047630
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $6,463.60 08/14/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1244047632
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $305.20 08/14/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1244047634
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $74.20 08/14/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1244047636
Principal investigator 1 ABBVIE INC. $2,369.15 08/13/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
A 52-week, Phase 2, Open-label Trial to Evaluate the Long-term Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia No dispute reported 06/30/2026 1202504535
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $168.00 08/08/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242356812
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,430.00 08/08/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242356824
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,430.00 08/08/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242356826
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,430.00 08/08/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242356828
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,430.00 08/08/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242356830
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,430.00 08/08/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242356832
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $4,620.00 08/07/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1244047626
Principal investigator 1 ABBVIE INC. $750.00 08/06/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
A 52-week, Phase 2, Open-label Trial to Evaluate the Long-term Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia No dispute reported 06/30/2026 1202503631
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $145,803.63 07/30/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1244047624
Principal investigator 1 Boehringer Ingelheim International GmbH $2,006.00 07/28/2025 Non-covered Recipient Entity
Galiz Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220685195
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 07/28/2025 Non-covered Recipient Entity
Galiz Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220685197
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 07/28/2025 Non-covered Recipient Entity
Galiz Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220685199
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $146.00 07/25/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242355480
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $80.00 07/25/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242355482
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $196.00 07/25/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242355484
Principal investigator 1 Boehringer Ingelheim International GmbH $2,500.00 07/23/2025 Non-covered Recipient Entity
Galiz Research
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220685171
Principal investigator 1 Boehringer Ingelheim International GmbH $500.00 07/23/2025 Non-covered Recipient Entity
Galiz Research
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220685181
Principal investigator 1 LivaNova USA, Inc. $1,345.00 07/22/2025 Non-covered Recipient Entity
Advarra, Inc. (Central IRB)
RECOVER: A PRospective, Multi-cEnter, Randomized Controlled Blinded Trial DemOnstrating the Safety and Effectiveness of VNS Therapy System as AdjunctivE Therapy Versus a No-Stimulation Control in Subjects With Treatment-Resistant Depression No dispute reported 06/30/2026 1245556911
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $800.00 07/22/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1244047622
Principal investigator 1 Boehringer Ingelheim International GmbH $9,500.00 07/18/2025 Non-covered Recipient Entity
Galiz Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220685193
Principal investigator 1 Boehringer Ingelheim International GmbH $483.68 07/16/2025 Non-covered Recipient Entity
Galiz Research
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220685183
Principal investigator 1 Janssen Research & Development, LLC $2,400.00 07/14/2025 Non-covered Recipient Entity
Galiz Research, Llc
A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of Aticaprant 10 mg and 5 mg as Adjunctive Therapy in Adult Participants with Major Depressive Disorder (MDD) with Moderate to Severe Anhedonia and Inadequate Response to Current Antidepressant Therapy. No dispute reported 06/30/2026 1175190948
Principal investigator 1 ABBVIE INC. $1,995.00 07/09/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
A 52-week, Phase 2, Open-label Trial to Evaluate the Long-term Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia No dispute reported 06/30/2026 1202497730
Principal investigator 1 ABBVIE INC. $6,468.40 07/09/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
A 52-week, Phase 2, Open-label Trial to Evaluate the Long-term Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia No dispute reported 06/30/2026 1202497732
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,360.00 07/07/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242352889
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,538.00 07/07/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242352891
Principal investigator 1 Boehringer Ingelheim International GmbH $2,500.00 07/02/2025 Non-covered Recipient Entity
Galiz Research
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220685173
Principal investigator 1 Boehringer Ingelheim International GmbH $2,100.00 07/02/2025 Non-covered Recipient Entity
Galiz Research
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220685175
Principal investigator 1 Boehringer Ingelheim International GmbH $1,250.00 07/02/2025 Non-covered Recipient Entity
Galiz Research
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220685177
Principal investigator 1 Boehringer Ingelheim International GmbH $1,250.00 07/02/2025 Non-covered Recipient Entity
Galiz Research
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220685179
Principal investigator 1 Novo Nordisk AS $3,143.70 06/23/2025 Non-covered Recipient Entity
GALIZ RESEARCH, LLC
NN6535-4725 No dispute reported 06/30/2026 1213815114
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $745.00 06/19/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1244047614
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,806.00 06/19/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1244047616
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,500.00 06/19/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1244047618
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $7,248.00 06/19/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1244047620
Principal investigator 1 ABBVIE INC. $78,733.84 06/18/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
A 52-week, Phase 2, Open-label Trial to Evaluate the Long-term Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia No dispute reported 06/30/2026 1202492397
Principal investigator 1 LivaNova USA, Inc. $90.00 06/17/2025 Non-covered Recipient Entity
Advarra, Inc. (Central IRB)
RECOVER: A PRospective, Multi-cEnter, Randomized Controlled Blinded Trial DemOnstrating the Safety and Effectiveness of VNS Therapy System as AdjunctivE Therapy Versus a No-Stimulation Control in Subjects With Treatment-Resistant Depression No dispute reported 06/30/2026 1245556846
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,360.00 06/13/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242350368
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,430.00 06/13/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242350396
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $6,643.00 06/13/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242350398
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,430.00 06/13/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242350400
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,430.00 06/13/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242350402
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,430.00 06/13/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242350404
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $7,550.00 06/13/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242350406
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,430.00 06/13/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242350434
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,430.00 06/13/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242350436
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,430.00 06/13/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242350438
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,430.00 06/13/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242350440
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,430.00 06/13/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242350442
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,430.00 06/13/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242350444
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,165.00 06/13/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242350446
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,430.00 06/13/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242350474
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,430.00 06/13/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242350476
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,430.00 06/13/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242350478
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,430.00 06/13/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242350480
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,430.00 06/13/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242350482
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,430.00 06/13/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242350484
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,430.00 06/13/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242350486
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $4,914.00 06/13/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242350488
Principal investigator 1 Boehringer Ingelheim International GmbH $106.00 06/11/2025 Non-covered Recipient Entity
Galiz Research
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220685165
Principal investigator 1 Boehringer Ingelheim International GmbH $106.00 06/11/2025 Non-covered Recipient Entity
Galiz Research
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220685167
Principal investigator 1 Boehringer Ingelheim International GmbH $106.00 06/11/2025 Non-covered Recipient Entity
Galiz Research
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220685169
Principal investigator 1 Boehringer Ingelheim International GmbH $264.55 06/10/2025 Non-covered Recipient Entity
Galiz Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220685347
Principal investigator 1 LivaNova USA, Inc. $1,189.50 06/07/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
RECOVER No dispute reported 06/30/2026 1245543523
Principal investigator 1 LivaNova USA, Inc. $97.50 06/07/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
RECOVER No dispute reported 06/30/2026 1245543528
Principal investigator 1 Janssen Research & Development, LLC $2,000.00 06/04/2025 Non-covered Recipient Entity
Galiz Research, Llc
A Study of Aticaprant in Adult and Elderly Participants With Major Depressive Disorder (MDD) (VENTURA-LT) No dispute reported 06/30/2026 1175191224
Principal investigator 1 ABBVIE INC. $1,327.45 05/15/2025 Non-covered Recipient Entity
GALIZ RESEARCH - PALMETTO MEDICAL PLAZA
Open-Label Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1202484965
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,430.00 05/07/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242346725
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,430.00 05/07/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242346727
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,430.00 05/07/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242346729
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,430.00 05/07/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242346731
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,430.00 05/07/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242346771
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $8,896.00 05/07/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242346773
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,430.00 05/07/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242346775
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,430.00 05/07/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242346777
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,430.00 05/07/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242346779
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,430.00 05/07/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242346781
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,430.00 05/07/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242346783
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,430.00 05/07/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242346825
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,430.00 05/07/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242346827
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $6,643.00 05/07/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242346829
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,430.00 05/07/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242346831
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,430.00 05/07/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242346833
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,430.00 05/07/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242346835
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $7,550.00 05/07/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242346837
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,430.00 05/07/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242346839
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,430.00 05/07/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242346881
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,430.00 05/07/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242346883
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,430.00 05/07/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242346885
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,430.00 05/07/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242346887
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,165.00 05/07/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242346889
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,430.00 05/07/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242346891
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,430.00 05/07/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242346893
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,430.00 05/07/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242346931
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,430.00 05/07/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242346933
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,430.00 05/07/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242346935
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,430.00 05/07/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242346937
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,430.00 05/07/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242346939
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $4,914.00 05/07/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242346941
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,430.00 05/07/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242346943
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,538.00 05/07/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242346945
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $8,105.00 05/07/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242346976
Principal investigator 1 Janssen Research & Development, LLC $3,604.00 05/02/2025 Non-covered Recipient Entity
Galiz Research, Llc
A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of Aticaprant 10 mg and 5 mg as Adjunctive Therapy in Adult Participants with Major Depressive Disorder (MDD) with Moderate to Severe Anhedonia and Inadequate Response to Current Antidepressant Therapy. No dispute reported 06/30/2026 1175190932
Principal investigator 1 Boehringer Ingelheim International GmbH $25.00 05/01/2025 Non-covered Recipient Entity
Galiz Research
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220685161
Principal investigator 1 Boehringer Ingelheim International GmbH $25.00 05/01/2025 Non-covered Recipient Entity
Galiz Research
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220685163
Principal investigator 1 Janssen Research & Development, LLC $6,535.00 04/23/2025 Non-covered Recipient Entity
Galiz Research, Llc
A Study of Aticaprant in Adult and Elderly Participants With Major Depressive Disorder (MDD) (VENTURA-LT) No dispute reported 06/30/2026 1175190923
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $23,433.37 04/16/2025 Non-covered Recipient Entity
Galiz Research, Llc
A Phase 3, Randomized, Double-blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT for the Treatment of Psychosis Associated with Alzheimers Disease Dementia No dispute reported 06/30/2026 1235997235
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,430.00 04/11/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242342957
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,430.00 04/11/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242342959
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,430.00 04/11/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242342975
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $8,105.00 04/11/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242342977
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,430.00 04/11/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242342979
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $6,643.00 04/11/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242342981
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,430.00 04/11/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242342989
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,430.00 04/11/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242342991
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,430.00 04/11/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242342993
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,430.00 04/11/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242342995
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $7,550.00 04/11/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242342997
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,430.00 04/11/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242342999
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,430.00 04/11/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242343007
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,430.00 04/11/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242343009
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,430.00 04/11/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242343021
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,430.00 04/11/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242343035
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,430.00 04/11/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242343037
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,430.00 04/11/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242343041
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,430.00 04/11/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242343043
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,430.00 04/11/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242343045
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,430.00 04/11/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242343047
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,430.00 04/11/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242343049
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,430.00 04/11/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242343051
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,430.00 04/11/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242343053
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,430.00 04/11/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242343075
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,430.00 04/11/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242343077
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,430.00 04/11/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242343097
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $4,914.00 04/11/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242343099
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,538.00 04/11/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242343101
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $8,105.00 04/11/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242343103
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,430.00 04/11/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242343215
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,430.00 04/11/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242343229
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,430.00 04/11/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242343231
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,430.00 04/11/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242343233
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $8,896.00 04/11/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242343261
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,430.00 04/11/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242343265
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,430.00 04/11/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242343267
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $8,896.00 04/11/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242343269
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,430.00 04/11/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242343271
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,430.00 04/11/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242343275
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,430.00 04/11/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242343277
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,430.00 04/11/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242343279
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,430.00 04/11/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242343281
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,430.00 04/11/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242343283
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $8,896.00 04/11/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242343285
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $7,550.00 04/11/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242343287
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,430.00 04/11/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242343289
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,430.00 04/11/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242343293
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,430.00 04/11/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242343295
Principal investigator 1 ABBVIE INC. $375.00 04/09/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
A 52-week, Phase 2, Open-label Trial to Evaluate the Long-term Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia No dispute reported 06/30/2026 1202475283
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $1,500.00 04/04/2025 Non-covered Recipient Entity
Advarra
A Randomized, Double-blind, Placebo-controlled, Global Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986446, an Anti-MTBR Tau Monoclonal Antibody, in Participants with Early Alzheimers Disease (TargetTau-1) No dispute reported 06/30/2026 1235999253
Principal investigator 1 Janssen Research & Development, LLC $5,052.00 04/02/2025 Non-covered Recipient Entity
Galiz Research, Llc
A Study of Aticaprant in Adult and Elderly Participants With Major Depressive Disorder (MDD) (VENTURA-LT) No dispute reported 06/30/2026 1175191359
Principal investigator 1 Boehringer Ingelheim International GmbH $49.00 04/01/2025 Non-covered Recipient Entity
Galiz Research
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220685153
Principal investigator 1 Boehringer Ingelheim International GmbH $49.00 04/01/2025 Non-covered Recipient Entity
Galiz Research
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220685155
Principal investigator 1 Boehringer Ingelheim International GmbH $25.00 04/01/2025 Non-covered Recipient Entity
Galiz Research
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220685157
Principal investigator 1 Boehringer Ingelheim International GmbH $25.00 04/01/2025 Non-covered Recipient Entity
Galiz Research
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220685159
Principal investigator 1 Boehringer Ingelheim International GmbH $40.00 03/31/2025 Non-covered Recipient Entity
Galiz Research
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220685149
Principal investigator 1 Boehringer Ingelheim International GmbH $143.00 03/26/2025 Non-covered Recipient Entity
Galiz Research
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220685143
Principal investigator 1 Boehringer Ingelheim International GmbH $429.00 03/26/2025 Non-covered Recipient Entity
Galiz Research
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220685151
Principal investigator 1 ABBVIE INC. $59,573.99 03/19/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
A 52-week, Phase 2, Open-label Trial to Evaluate the Long-term Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia No dispute reported 06/30/2026 1202464629
Principal investigator 1 ABBVIE INC. $11,332.49 03/19/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
A 52-week, Phase 2, Open-label Trial to Evaluate the Long-term Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia No dispute reported 06/30/2026 1202464633
Principal investigator 1 ABBVIE INC. $781.30 03/19/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
A 52-week, Phase 2, Open-label Trial to Evaluate the Long-term Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia No dispute reported 06/30/2026 1202464645
Principal investigator 1 ABBVIE INC. $20,353.21 03/19/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
A 52-week, Phase 2, Open-label Trial to Evaluate the Long-term Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia No dispute reported 06/30/2026 1202464650
Principal investigator 1 ABBVIE INC. $3,925.10 03/19/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
A 52-week, Phase 2, Open-label Trial to Evaluate the Long-term Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia No dispute reported 06/30/2026 1202464653
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $34,321.06 03/12/2025 Non-covered Recipient Entity
Galiz Research, Llc
A Randomized, Double-blind, Placebo-controlled, Global Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986446, an Anti-MTBR Tau Monoclonal Antibody, in Participants with Early Alzheimers Disease (TargetTau-1) No dispute reported 06/30/2026 1235997237
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $1,777.00 03/12/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242336729
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $8,826.00 03/12/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242336731
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,360.00 03/12/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242336733
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,360.00 03/12/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242336735
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $8,826.00 03/12/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242336737
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,360.00 03/12/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242336739
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,360.00 03/12/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242336741
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,360.00 03/12/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242336743
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,360.00 03/12/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242336835
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,360.00 03/12/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242336837
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,360.00 03/12/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242336839
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $53.00 03/12/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242336841
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $53.00 03/12/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242336925
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,538.00 03/12/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242336927
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,360.00 03/12/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242336929
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,360.00 03/12/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242337005
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,360.00 03/12/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242337007
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,360.00 03/12/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242337009
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,360.00 03/12/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242337011
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $7,480.00 03/12/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242337013
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,360.00 03/12/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242337015
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,360.00 03/12/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242337017
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,360.00 03/12/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242337079
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,360.00 03/12/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242337081
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,360.00 03/12/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242337083
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,360.00 03/12/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242337085
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,165.00 03/12/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242337087
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,360.00 03/12/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242337089
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,360.00 03/12/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242337091
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,360.00 03/12/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242337093
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,360.00 03/12/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242337157
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,360.00 03/12/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242337159
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,360.00 03/12/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242337161
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,360.00 03/12/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242337163
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $4,914.00 03/12/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242337165
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,538.00 03/12/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242337167
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $120.00 03/12/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242337169
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $106.00 03/12/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242337229
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $8,035.00 03/12/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242337231
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $6,573.00 03/12/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242337233
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $7,480.00 03/12/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242337235
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,165.00 03/12/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242337237
Principal investigator 1 ABBVIE INC. $4,525.00 03/05/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
A 52-week, Phase 2, Open-label Trial to Evaluate the Long-term Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia No dispute reported 06/30/2026 1202456222
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $62,000.00 03/04/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1244047610
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $6,200.00 03/04/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1244047612
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,360.00 03/03/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242334256
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,360.00 03/03/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242334260
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,360.00 03/03/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242334262
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,360.00 03/03/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242334264
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $8,826.00 03/03/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242334266
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,360.00 03/03/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242334268
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,360.00 03/03/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242334270
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,360.00 03/03/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242334272
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,360.00 03/03/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242334274
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,360.00 03/03/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242334276
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,360.00 03/03/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242334278
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,360.00 03/03/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242334280
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,360.00 03/03/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242334282
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,360.00 03/03/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242334284
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $7,480.00 03/03/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242334286
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,360.00 03/03/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242334288
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,360.00 03/03/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242334290
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,360.00 03/03/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242334292
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,360.00 03/03/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242334294
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,360.00 03/03/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242334296
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,360.00 03/03/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242334298
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,360.00 03/03/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242334300
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $4,914.00 03/03/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242334302
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,538.00 03/03/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242334304
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $8,035.00 03/03/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242334306
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $6,573.00 03/03/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242334308
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,360.00 03/03/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242334310
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,360.00 03/03/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242334312
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,360.00 03/03/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242334314
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,360.00 03/03/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242334316
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,360.00 03/03/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242334318
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,360.00 03/03/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242334320
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,360.00 03/03/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242334322
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,360.00 03/03/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242334324
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,360.00 03/03/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242334326
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,165.00 03/03/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242334328
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,360.00 03/03/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242334330
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,360.00 03/03/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242334332
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,360.00 03/03/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242334334
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,360.00 03/03/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242334342
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,360.00 03/03/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242334356
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,360.00 03/03/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242334358
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $8,826.00 03/03/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242334372
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,360.00 03/03/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242334374
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $7,480.00 03/03/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242334376
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,360.00 03/03/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242334378
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,360.00 03/03/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242334380
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,360.00 03/03/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242334382
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,360.00 03/03/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242334384
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,360.00 03/03/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242334386
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,360.00 03/03/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242334388
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,165.00 03/03/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242334390
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,360.00 03/03/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242334392
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $46.00 03/03/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242334394
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $8,035.00 03/03/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242334396
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $6,573.00 03/03/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242334398
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,360.00 03/03/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242334406
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,360.00 03/03/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242334408
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,360.00 03/03/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242334410
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,360.00 03/03/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242334412
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,360.00 03/03/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242334414
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,360.00 03/03/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242334416
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $4,914.00 03/03/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242334418
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $1,777.00 03/03/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242334420
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $1,777.00 03/03/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242334422
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $106.00 03/03/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242334424
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $106.00 03/03/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242334426
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $106.00 03/03/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242334428
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $106.00 03/03/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242334430
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $106.00 03/03/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242334432
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $120.00 03/03/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242334434
Principal investigator 1 Janssen Research & Development, LLC $1,783.00 03/03/2025 Non-covered Recipient Entity
Galiz Research, Llc
A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of Aticaprant 10 mg and 5 mg as Adjunctive Therapy in Adult Participants with Major Depressive Disorder (MDD) with Moderate to Severe Anhedonia and Inadequate Response to Current Antidepressant Therapy. No dispute reported 06/30/2026 1175191323
Principal investigator 1 Boehringer Ingelheim International GmbH $49.00 03/01/2025 Non-covered Recipient Entity
Galiz Research
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220685135
Principal investigator 1 Boehringer Ingelheim International GmbH $49.00 03/01/2025 Non-covered Recipient Entity
Galiz Research
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220685137
Principal investigator 1 Boehringer Ingelheim International GmbH $25.00 03/01/2025 Non-covered Recipient Entity
Galiz Research
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220685139
Principal investigator 1 Boehringer Ingelheim International GmbH $25.00 03/01/2025 Non-covered Recipient Entity
Galiz Research
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220685141
Principal investigator 1 Boehringer Ingelheim International GmbH $40.00 02/28/2025 Non-covered Recipient Entity
Galiz Research
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220685147
Principal investigator 1 Janssen Research & Development, LLC $4,570.00 02/24/2025 Non-covered Recipient Entity
Galiz Research, Llc
A Study of Aticaprant in Adult and Elderly Participants With Major Depressive Disorder (MDD) (VENTURA-LT) No dispute reported 06/30/2026 1175191190
Principal investigator 1 Novo Nordisk AS $747.90 02/21/2025 Non-covered Recipient Entity
GALIZ RESEARCH, LLC
NN6535-4725 No dispute reported 06/30/2026 1213770567
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $2,650.00 02/20/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1244047602
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $4,899.00 02/20/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1244047604
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $3,200.00 02/20/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1244047606
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $415.00 02/20/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1244047608
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $27,735.40 02/11/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1244047598
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $806.40 02/11/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1244047600
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $62,358.42 02/05/2025 Non-covered Recipient Entity
Galiz Research, Llc
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects with Psychosis Associated with Alzheimers Disease Dementia No dispute reported 06/30/2026 1235997233
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $949.20 02/05/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1244047592
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,210.00 02/05/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1244047594
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $800.00 02/05/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1244047596
Principal investigator 1 Boehringer Ingelheim International GmbH $49.00 02/01/2025 Non-covered Recipient Entity
Galiz Research
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220685127
Principal investigator 1 Boehringer Ingelheim International GmbH $49.00 02/01/2025 Non-covered Recipient Entity
Galiz Research
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220685129
Principal investigator 1 Boehringer Ingelheim International GmbH $25.00 02/01/2025 Non-covered Recipient Entity
Galiz Research
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220685131
Principal investigator 1 Boehringer Ingelheim International GmbH $25.00 02/01/2025 Non-covered Recipient Entity
Galiz Research
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220685133
Principal investigator 1 Boehringer Ingelheim International GmbH $40.00 01/31/2025 Non-covered Recipient Entity
Galiz Research
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220685145
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $1,392.22 01/27/2025 Non-covered Recipient Entity
Galiz Research, Llc
A Randomized, Double-blind, Placebo-controlled, Global Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986446, an Anti-MTBR Tau Monoclonal Antibody, in Participants with Early Alzheimers Disease (TargetTau-1) No dispute reported 06/30/2026 1235997239
Principal investigator 1 Janssen Research & Development, LLC $6,427.00 01/24/2025 Non-covered Recipient Entity
Galiz Research, Llc
A Study of Aticaprant in Adult and Elderly Participants With Major Depressive Disorder (MDD) (VENTURA-LT) No dispute reported 06/30/2026 1175191289
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,360.00 01/22/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242328853
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,360.00 01/22/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242328855
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,360.00 01/22/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242328901
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,360.00 01/22/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242328903
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,360.00 01/22/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242328905
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,360.00 01/22/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242328907
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,360.00 01/22/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242328909
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,360.00 01/22/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242328911
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,360.00 01/22/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242328913
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,360.00 01/22/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242328975
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,360.00 01/22/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242328977
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $8,826.00 01/22/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242328979
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,360.00 01/22/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242328981
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,360.00 01/22/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242328983
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,360.00 01/22/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242328985
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,360.00 01/22/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242328987
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $8,826.00 01/22/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242328989
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,360.00 01/22/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242329053
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,360.00 01/22/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242329055
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,360.00 01/22/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242329057
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,360.00 01/22/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242329059
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,360.00 01/22/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242329061
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,360.00 01/22/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242329063
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,360.00 01/22/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242329065
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,360.00 01/22/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242329129
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,360.00 01/22/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242329131
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,360.00 01/22/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242329133
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,360.00 01/22/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242329135
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,360.00 01/22/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242329137
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,360.00 01/22/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242329139
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,360.00 01/22/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242329141
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,360.00 01/22/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242329143
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,360.00 01/22/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242329209
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,165.00 01/22/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242329211
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,360.00 01/22/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242329213
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,360.00 01/22/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242329215
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,360.00 01/22/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242329217
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,360.00 01/22/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242329219
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,360.00 01/22/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242329221
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,360.00 01/22/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242329281
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,360.00 01/22/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242329283
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $4,914.00 01/22/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242329285
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $8,035.00 01/22/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242329287
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,360.00 01/22/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242329289
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,360.00 01/22/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242329291
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,360.00 01/22/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242329293
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,360.00 01/22/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242329295
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,360.00 01/22/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242329365
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,360.00 01/22/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242329367
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,360.00 01/22/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242329369
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,360.00 01/22/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242329371
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,360.00 01/22/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242329373
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,360.00 01/22/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242329375
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,360.00 01/22/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242329377
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,360.00 01/22/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242329435
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,360.00 01/22/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242329437
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,360.00 01/22/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242329439
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,360.00 01/22/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242329441
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,360.00 01/22/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242329443
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $4,914.00 01/22/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242329445
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $53.00 01/22/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242329447
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $8,035.00 01/22/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242329449
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,360.00 01/22/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242329503
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $6,573.00 01/22/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242329505
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,360.00 01/22/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
ITI-007-451 No dispute reported 06/30/2026 1242329507
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $2,845.08 01/21/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1244047590
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $138,579.09 01/17/2025 Non-covered Recipient Entity
Galiz Research, Llc
An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia No dispute reported 06/30/2026 1235997229
Principal investigator 1 Boehringer Ingelheim International GmbH $4,686.00 01/15/2025 Non-covered Recipient Entity
Galiz Research
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220685113
Principal investigator 1 Boehringer Ingelheim International GmbH $4,185.00 01/15/2025 Non-covered Recipient Entity
Galiz Research
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220685115
Principal investigator 1 Boehringer Ingelheim International GmbH $3,385.00 01/15/2025 Non-covered Recipient Entity
Galiz Research
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220685117
Principal investigator 1 Janssen Research & Development, LLC $2,550.00 01/10/2025 Non-covered Recipient Entity
Galiz Research, Llc
A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of Aticaprant 10 mg and 5 mg as Adjunctive Therapy in Adult Participants with Major Depressive Disorder (MDD) with Moderate to Severe Anhedonia and Inadequate Response to Current Antidepressant Therapy. No dispute reported 06/30/2026 1175191170
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $4,149.18 01/07/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1244047586
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $2,845.08 01/07/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy, Safety, and Tolerability of Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use as Treatment of Adult Patients With Schizophrenia No dispute reported 06/30/2026 1244047588
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $98,911.08 01/06/2025 Non-covered Recipient Entity
Galiz Research, Llc
A Study to Assess Efficacy and Safety of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia (ARISE) No dispute reported 06/30/2026 1235997231
Principal investigator 1 ABBVIE INC. $74.00 01/03/2025 Non-covered Recipient Entity
GALIZ RESEARCH LLC
A 52-week, Phase 2, Open-label Trial to Evaluate the Long-term Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia No dispute reported 06/30/2026 1202436661
Principal investigator 1 Janssen Research & Development, LLC $305.00 01/03/2025 Non-covered Recipient Entity
Galiz Research, Llc
A Study of Aticaprant in Adult and Elderly Participants With Major Depressive Disorder (MDD) (VENTURA-LT) No dispute reported 06/30/2026 1175191376
Principal investigator 1 Boehringer Ingelheim International GmbH $49.00 01/01/2025 Non-covered Recipient Entity
Galiz Research
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220685119
Principal investigator 1 Boehringer Ingelheim International GmbH $49.00 01/01/2025 Non-covered Recipient Entity
Galiz Research
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220685121
Principal investigator 1 Boehringer Ingelheim International GmbH $25.00 01/01/2025 Non-covered Recipient Entity
Galiz Research
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220685123
Principal investigator 1 Boehringer Ingelheim International GmbH $25.00 01/01/2025 Non-covered Recipient Entity
Galiz Research
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD No dispute reported 06/30/2026 1220685125